The purpose of the study was to determine the effect of anti-inflammatory doses of ibuprofen on neutrophils, neutrophil O2* production, and markers of muscle injury. Males (n=10) performed 2 bouts of one-arm eccentric exercise on opposite arms separated by three weeks. Subjects received 2400 mg x d(-1) of ibuprofen or a placebo 5 d before exercise and during 10 d of recovery. Measurements were made before the treatments, pre-exercise, at 4 h, and at 1, 2, 3, 4 and 10 d post-exercise. Circulating neutrophil counts were similar between the treatments at the sampling points. Neutrophil counts were higher (p<0.05) for ibuprofen and were elevated (p<0.05) at 4h post-exercise relative to pre-exercise in both treatments. Stimulated neutrophil O2* production was lower for ibuprofen relative to placebo at pre-exercise and was increased (p<0.05) at 4 h and 4 d of both treatments. CK activity at 3 d post-exercise was lower (p<0.05) for ibuprofen relative to placebo. Isometric strength, soreness, tenderness, and arm angles were similar between the treatments. In conclusion, anti-inflammatory doses of ibuprofen reduced CK activity but not the neutrophil response or other indirect markers of muscle injury during recovery from eccentric arm exercise.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/s-2007-971100 | DOI Listing |
BMC Complement Med Ther
January 2025
School of Pharmaceutical Sciences, University Sains Malaysia, Gelugor, Malaysia.
Background: Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD) characterized by damage and inflammation of hepatocytes. Some medicinal plants have shown antioxidant and anti-inflammatory effects on liver cells. We aimed to investigate the hepatoprotective effect of Heptex® capsules containing 200 mg of Dukung Anak (a powdered extract from aerial parts of Phyllanthus niruri) and 100 mg of Milk Thistle (a powdered extract from fruits of Silybum marianum) in patients with an apparent risk factor for NASH.
View Article and Find Full Text PDFAAPS J
January 2025
Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, 160 Hayes Rd, Buffalo, New York, 14214, USA.
The study quantitatively analyzes and compares the pharmacokinetics (PK) of methylprednisolone (MPL) in humans upon administration of various dosage forms. The PK parameters and profiles of MPL in healthy subjects were collected from 22 literature sources. A minimal physiologically based pharmacokinetic (mPBPK) model consisting of blood and two tissue (lumped liver and kidney, remainder) compartments with nonlinear tissue partitioning was applied to describe MPL disposition.
View Article and Find Full Text PDFIntern Med J
January 2025
Department of Rheumatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Background: Immune checkpoint inhibitors (ICIs) have significantly improved cancer treatment outcomes but are associated with immune-related adverse events (irAEs), such as inflammatory arthritis (ir-IA). Management of ir-IA is evolving, with corticosteroids as the primary treatment, though some cases require steroid-sparing agents.
Aims: This study aimed to compare initial mean prednisolone doses and disease persistence over 12 months in patients with rheumatoid arthritis (RA)-like ir-IA managed by rheumatologists or oncologists.
Background: Selecting the optimal dose for clinical development is especially problematic for drugs directed at CNS-specific targets. For drugs with a novel mechanism of action, these problems are often greater. We describe Xanamem's clinical pharmacology, including the approach to dose selection and proof-of-concept studies.
View Article and Find Full Text PDFBackground: TREM2 is a lipid-sensing receptor expressed by microglial sub-populations within neuropathological microenvironments, whose downstream signaling promotes microglial survival, plasticity, and migration. Multiple loss-of-function variants strongly implicate TREM2 as a key regulator of Alzheimer's disease (AD) risk. Accordingly, TREM2 antibodies are currently in development to evaluate the therapeutic potential of TREM2 agonism in neurodegenerative diseases.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!